Dianthus Therapeutics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Dianthus Therapeutics, Inc. Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company that develops next-generation antibody therapeutics targeting the complement system and related immune pathways for patients with severe autoimmune diseases. Founded in 2019 and headquartered in New York City with additional offices in Waltham, Massachusetts, the company advances a pipeline featuring its lead candidate claseprubart (DNTH103), an investigational, long-acting monoclonal antibody engineered with YTE half-life extension technology for selective inhibition of active C1s in the classical complement pathway, enabling self-administered subcutaneous dosing as infrequently as every two or four weeks; and DNTH212, an investigational extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production while inhibiting BAFF/APRIL signaling to suppress B cell function, also designed for infrequent self-administration every four weeks. Claseprubart targets neuromuscular disorders driven by classical pathway activation, including generalized myasthenia gravis in a Phase 3 trial initiating in 2026, chronic inflammatory demyelinating polyneuropathy with an accelerated Phase 3 interim analysis in Q2 2026, and multifocal motor neuropathy with Phase 2 top-line data expected in 2H 2026; DNTH212 advances in a two-part Phase 1 study in China for healthy volunteers and systemic lupus erythematosus patients initiating by year-end 2025, with top-line healthy volunteer data in 2H 2026. Recent developments include positive Phase 2 MaGic trial results for claseprubart in generalized myasthenia gravis reported in September 2025, demonstrating statistically significant improvements in key efficacy measures versus placebo with favorable safety; an exclusive license agreement in October 2025 with Nanjing Leads Biolabs Co., Ltd. for DNTH212 involving up to $38 million upfront and near-term payments plus up to $962 million in milestones and royalties outside Greater China; closure of an upsized $288 million public offering in September 2025; and a pro forma cash position of approximately $525 million as of September 30, 2025, supporting operations into 2028.
Company News
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics to Participate in Two Investor Conferences